nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—embryo—testicular cancer	0.00727	0.206	CbGeAlD
Methyldopa—COMT—seminal vesicle—testicular cancer	0.00451	0.128	CbGeAlD
Methyldopa—DDC—testis—testicular cancer	0.00356	0.101	CbGeAlD
Methyldopa—Infestation NOS—Etoposide—testicular cancer	0.00344	0.00356	CcSEcCtD
Methyldopa—Infestation—Etoposide—testicular cancer	0.00344	0.00356	CcSEcCtD
Methyldopa—Bradycardia—Cisplatin—testicular cancer	0.00343	0.00355	CcSEcCtD
Methyldopa—Mental disorder—Ifosfamide—testicular cancer	0.00342	0.00355	CcSEcCtD
Methyldopa—Myalgia—Bleomycin—testicular cancer	0.00339	0.00351	CcSEcCtD
Methyldopa—Jaundice—Etoposide—testicular cancer	0.00335	0.00347	CcSEcCtD
Methyldopa—Leukopenia—Dactinomycin—testicular cancer	0.00332	0.00344	CcSEcCtD
Methyldopa—Body temperature increased—Chlorambucil—testicular cancer	0.00332	0.00344	CcSEcCtD
Methyldopa—Connective tissue disorder—Cisplatin—testicular cancer	0.00331	0.00343	CcSEcCtD
Methyldopa—Colitis—Epirubicin—testicular cancer	0.00331	0.00343	CcSEcCtD
Methyldopa—Gynaecomastia—Methotrexate—testicular cancer	0.00329	0.00341	CcSEcCtD
Methyldopa—Constipation—Vinblastine—testicular cancer	0.00329	0.00341	CcSEcCtD
Methyldopa—COMT—gonad—testicular cancer	0.00326	0.0925	CbGeAlD
Methyldopa—Hepatobiliary disease—Etoposide—testicular cancer	0.00325	0.00337	CcSEcCtD
Methyldopa—Oedema—Bleomycin—testicular cancer	0.00325	0.00336	CcSEcCtD
Methyldopa—Infection—Bleomycin—testicular cancer	0.00322	0.00334	CcSEcCtD
Methyldopa—Agranulocytosis—Etoposide—testicular cancer	0.00321	0.00332	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—testicular cancer	0.00319	0.0033	CcSEcCtD
Methyldopa—Thrombocytopenia—Bleomycin—testicular cancer	0.00318	0.00329	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—testicular cancer	0.00316	0.00327	CcSEcCtD
Methyldopa—Cardiac disorder—Cisplatin—testicular cancer	0.00312	0.00324	CcSEcCtD
Methyldopa—Hypersensitivity—Chlorambucil—testicular cancer	0.00309	0.0032	CcSEcCtD
Methyldopa—Colitis—Doxorubicin—testicular cancer	0.00306	0.00317	CcSEcCtD
Methyldopa—Leukopenia—Ifosfamide—testicular cancer	0.00304	0.00315	CcSEcCtD
Methyldopa—Mediastinal disorder—Cisplatin—testicular cancer	0.00303	0.00314	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—testicular cancer	0.00303	0.00314	CcSEcCtD
Methyldopa—Asthenia—Chlorambucil—testicular cancer	0.00301	0.00312	CcSEcCtD
Methyldopa—Infection—Dactinomycin—testicular cancer	0.00301	0.00312	CcSEcCtD
Methyldopa—Thrombocytopenia—Dactinomycin—testicular cancer	0.00296	0.00307	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00296	0.00307	CcSEcCtD
Methyldopa—Paraesthesia—Bleomycin—testicular cancer	0.00291	0.00302	CcSEcCtD
Methyldopa—Arthralgia—Ifosfamide—testicular cancer	0.00289	0.003	CcSEcCtD
Methyldopa—Myalgia—Ifosfamide—testicular cancer	0.00289	0.003	CcSEcCtD
Methyldopa—Flatulence—Cisplatin—testicular cancer	0.00289	0.00299	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00287	0.00298	CcSEcCtD
Methyldopa—Diarrhoea—Chlorambucil—testicular cancer	0.00287	0.00297	CcSEcCtD
Methyldopa—Cardiac disorder—Etoposide—testicular cancer	0.00286	0.00297	CcSEcCtD
Methyldopa—Hypersensitivity—Vinblastine—testicular cancer	0.00283	0.00293	CcSEcCtD
Methyldopa—Angiopathy—Etoposide—testicular cancer	0.0028	0.0029	CcSEcCtD
Methyldopa—Eczema—Epirubicin—testicular cancer	0.00278	0.00288	CcSEcCtD
Methyldopa—Mediastinal disorder—Etoposide—testicular cancer	0.00278	0.00288	CcSEcCtD
Methyldopa—Oedema—Ifosfamide—testicular cancer	0.00277	0.00288	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00276	0.00286	CcSEcCtD
Methyldopa—Asthenia—Vinblastine—testicular cancer	0.00276	0.00286	CcSEcCtD
Methyldopa—Infection—Ifosfamide—testicular cancer	0.00276	0.00286	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—testicular cancer	0.00276	0.00286	CcSEcCtD
Methyldopa—Nervous system disorder—Ifosfamide—testicular cancer	0.00272	0.00282	CcSEcCtD
Methyldopa—Thrombocytopenia—Ifosfamide—testicular cancer	0.00272	0.00282	CcSEcCtD
Methyldopa—Skin disorder—Ifosfamide—testicular cancer	0.00269	0.00279	CcSEcCtD
Methyldopa—Vomiting—Chlorambucil—testicular cancer	0.00267	0.00276	CcSEcCtD
Methyldopa—COMT—female gonad—testicular cancer	0.00265	0.0752	CbGeAlD
Methyldopa—Diarrhoea—Vinblastine—testicular cancer	0.00263	0.00273	CcSEcCtD
Methyldopa—Leukopenia—Cisplatin—testicular cancer	0.00262	0.00272	CcSEcCtD
Methyldopa—DDC—lymph node—testicular cancer	0.00258	0.0731	CbGeAlD
Methyldopa—Eczema—Doxorubicin—testicular cancer	0.00257	0.00267	CcSEcCtD
Methyldopa—Body temperature increased—Bleomycin—testicular cancer	0.00257	0.00266	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—testicular cancer	0.00255	0.00264	CcSEcCtD
Methyldopa—Dizziness—Vinblastine—testicular cancer	0.00254	0.00263	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00253	0.00262	CcSEcCtD
Methyldopa—Myalgia—Cisplatin—testicular cancer	0.00249	0.00259	CcSEcCtD
Methyldopa—Nausea—Chlorambucil—testicular cancer	0.00249	0.00258	CcSEcCtD
Methyldopa—Paraesthesia—Ifosfamide—testicular cancer	0.00249	0.00258	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00248	0.00257	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—testicular cancer	0.00247	0.00256	CcSEcCtD
Methyldopa—Vomiting—Vinblastine—testicular cancer	0.00244	0.00253	CcSEcCtD
Methyldopa—Breast disorder—Methotrexate—testicular cancer	0.00241	0.0025	CcSEcCtD
Methyldopa—Headache—Vinblastine—testicular cancer	0.00241	0.0025	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.0024	0.00249	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—testicular cancer	0.0024	0.00249	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00239	0.00248	CcSEcCtD
Methyldopa—Body temperature increased—Dactinomycin—testicular cancer	0.00239	0.00248	CcSEcCtD
Methyldopa—Oedema—Cisplatin—testicular cancer	0.00239	0.00248	CcSEcCtD
Methyldopa—Hypersensitivity—Bleomycin—testicular cancer	0.00239	0.00248	CcSEcCtD
Methyldopa—Infection—Cisplatin—testicular cancer	0.00238	0.00246	CcSEcCtD
Methyldopa—Constipation—Ifosfamide—testicular cancer	0.00237	0.00246	CcSEcCtD
Methyldopa—COMT—testis—testicular cancer	0.00235	0.0667	CbGeAlD
Methyldopa—Nervous system disorder—Cisplatin—testicular cancer	0.00235	0.00243	CcSEcCtD
Methyldopa—Thrombocytopenia—Cisplatin—testicular cancer	0.00234	0.00243	CcSEcCtD
Methyldopa—Asthenia—Bleomycin—testicular cancer	0.00233	0.00241	CcSEcCtD
Methyldopa—Skin disorder—Cisplatin—testicular cancer	0.00232	0.00241	CcSEcCtD
Methyldopa—Liver function test abnormal—Epirubicin—testicular cancer	0.00231	0.00239	CcSEcCtD
Methyldopa—ADRA2A—seminal vesicle—testicular cancer	0.0023	0.0652	CbGeAlD
Methyldopa—Eosinophilia—Methotrexate—testicular cancer	0.00228	0.00237	CcSEcCtD
Methyldopa—Nausea—Vinblastine—testicular cancer	0.00228	0.00237	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—testicular cancer	0.00228	0.00237	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00227	0.00235	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—testicular cancer	0.00226	0.00235	CcSEcCtD
Methyldopa—Breast disorder—Epirubicin—testicular cancer	0.00226	0.00234	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00225	0.00233	CcSEcCtD
Methyldopa—Hypersensitivity—Dactinomycin—testicular cancer	0.00223	0.00231	CcSEcCtD
Methyldopa—Body temperature increased—Ifosfamide—testicular cancer	0.00219	0.00227	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—testicular cancer	0.00219	0.00227	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00218	0.00226	CcSEcCtD
Methyldopa—Infection—Etoposide—testicular cancer	0.00218	0.00226	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—testicular cancer	0.00217	0.00225	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—testicular cancer	0.00217	0.00225	CcSEcCtD
Methyldopa—Paraesthesia—Cisplatin—testicular cancer	0.00215	0.00223	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—testicular cancer	0.00215	0.00222	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—testicular cancer	0.00214	0.00222	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—testicular cancer	0.00213	0.00221	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—testicular cancer	0.00213	0.00221	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—testicular cancer	0.00213	0.0022	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—testicular cancer	0.00212	0.00219	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00211	0.00219	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—testicular cancer	0.0021	0.00218	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—testicular cancer	0.00209	0.00217	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00208	0.00216	CcSEcCtD
Methyldopa—Diarrhoea—Dactinomycin—testicular cancer	0.00207	0.00215	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00206	0.00214	CcSEcCtD
Methyldopa—Vomiting—Bleomycin—testicular cancer	0.00206	0.00214	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—testicular cancer	0.00206	0.00213	CcSEcCtD
Methyldopa—Infestation—Methotrexate—testicular cancer	0.00206	0.00213	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—testicular cancer	0.00205	0.00213	CcSEcCtD
Methyldopa—Rash—Bleomycin—testicular cancer	0.00205	0.00212	CcSEcCtD
Methyldopa—Dermatitis—Bleomycin—testicular cancer	0.00204	0.00212	CcSEcCtD
Methyldopa—Hypersensitivity—Ifosfamide—testicular cancer	0.00204	0.00212	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—testicular cancer	0.00201	0.00209	CcSEcCtD
Methyldopa—Asthenia—Ifosfamide—testicular cancer	0.00199	0.00206	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—testicular cancer	0.00198	0.00205	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—testicular cancer	0.00197	0.00204	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—testicular cancer	0.00197	0.00204	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—testicular cancer	0.00196	0.00203	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—testicular cancer	0.00195	0.00202	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—testicular cancer	0.00195	0.00202	CcSEcCtD
Methyldopa—Nausea—Bleomycin—testicular cancer	0.00193	0.002	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—testicular cancer	0.00193	0.002	CcSEcCtD
Methyldopa—Infestation—Epirubicin—testicular cancer	0.00193	0.002	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—testicular cancer	0.00192	0.002	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—testicular cancer	0.00192	0.00199	CcSEcCtD
Methyldopa—Rash—Dactinomycin—testicular cancer	0.00191	0.00198	CcSEcCtD
Methyldopa—Diarrhoea—Ifosfamide—testicular cancer	0.0019	0.00197	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—testicular cancer	0.0019	0.00197	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—testicular cancer	0.00189	0.00196	CcSEcCtD
Methyldopa—Body temperature increased—Cisplatin—testicular cancer	0.00189	0.00196	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—testicular cancer	0.00188	0.00195	CcSEcCtD
Methyldopa—Constipation—Etoposide—testicular cancer	0.00187	0.00194	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—testicular cancer	0.00185	0.00191	CcSEcCtD
Methyldopa—Dizziness—Ifosfamide—testicular cancer	0.00183	0.0019	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—testicular cancer	0.00182	0.00189	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—testicular cancer	0.00182	0.00189	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—testicular cancer	0.0018	0.00186	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—testicular cancer	0.0018	0.00186	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—testicular cancer	0.00178	0.00185	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—testicular cancer	0.00178	0.00185	CcSEcCtD
Methyldopa—Vomiting—Ifosfamide—testicular cancer	0.00176	0.00183	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—testicular cancer	0.00176	0.00183	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—testicular cancer	0.00176	0.00182	CcSEcCtD
Methyldopa—Rash—Ifosfamide—testicular cancer	0.00175	0.00181	CcSEcCtD
Methyldopa—Dermatitis—Ifosfamide—testicular cancer	0.00175	0.00181	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—testicular cancer	0.00174	0.0018	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—testicular cancer	0.00173	0.0018	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—testicular cancer	0.00173	0.00179	CcSEcCtD
Methyldopa—Asthenia—Cisplatin—testicular cancer	0.00172	0.00178	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—testicular cancer	0.00171	0.00178	CcSEcCtD
Methyldopa—COMT—lymph node—testicular cancer	0.0017	0.0483	CbGeAlD
Methyldopa—Connective tissue disorder—Epirubicin—testicular cancer	0.0017	0.00176	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00169	0.00175	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—testicular cancer	0.00168	0.00174	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—testicular cancer	0.00166	0.00173	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—testicular cancer	0.00166	0.00172	CcSEcCtD
Methyldopa—ADRA2A—gonad—testicular cancer	0.00166	0.0471	CbGeAlD
Methyldopa—Nausea—Ifosfamide—testicular cancer	0.00165	0.00171	CcSEcCtD
Methyldopa—Diarrhoea—Cisplatin—testicular cancer	0.00164	0.0017	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—testicular cancer	0.00163	0.00169	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—testicular cancer	0.00162	0.00168	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—testicular cancer	0.00161	0.00167	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—testicular cancer	0.0016	0.00166	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—testicular cancer	0.0016	0.00166	CcSEcCtD
Methyldopa—Asthenia—Etoposide—testicular cancer	0.00157	0.00163	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—testicular cancer	0.00157	0.00163	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—testicular cancer	0.00157	0.00163	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—testicular cancer	0.00156	0.00161	CcSEcCtD
Methyldopa—Vomiting—Cisplatin—testicular cancer	0.00152	0.00158	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—testicular cancer	0.00151	0.00157	CcSEcCtD
Methyldopa—Rash—Cisplatin—testicular cancer	0.00151	0.00156	CcSEcCtD
Methyldopa—Dermatitis—Cisplatin—testicular cancer	0.00151	0.00156	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—testicular cancer	0.0015	0.00155	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—testicular cancer	0.00148	0.00154	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—testicular cancer	0.00148	0.00154	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—testicular cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Dizziness—Etoposide—testicular cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—testicular cancer	0.00144	0.00149	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—testicular cancer	0.00144	0.00149	CcSEcCtD
Methyldopa—Nausea—Cisplatin—testicular cancer	0.00142	0.00147	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—testicular cancer	0.0014	0.00145	CcSEcCtD
Methyldopa—Vomiting—Etoposide—testicular cancer	0.00139	0.00144	CcSEcCtD
Methyldopa—Rash—Etoposide—testicular cancer	0.00138	0.00143	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—testicular cancer	0.00138	0.00143	CcSEcCtD
Methyldopa—Headache—Etoposide—testicular cancer	0.00137	0.00142	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—testicular cancer	0.00137	0.00142	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—testicular cancer	0.00137	0.00142	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—testicular cancer	0.00137	0.00142	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00136	0.00141	CcSEcCtD
Methyldopa—ADRA2A—female gonad—testicular cancer	0.00135	0.0383	CbGeAlD
Methyldopa—Leukopenia—Epirubicin—testicular cancer	0.00135	0.0014	CcSEcCtD
Methyldopa—Infection—Methotrexate—testicular cancer	0.0013	0.00135	CcSEcCtD
Methyldopa—Nausea—Etoposide—testicular cancer	0.0013	0.00135	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—testicular cancer	0.00129	0.00133	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—testicular cancer	0.00128	0.00133	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—testicular cancer	0.00128	0.00133	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—testicular cancer	0.00128	0.00133	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—testicular cancer	0.00127	0.00132	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00127	0.00132	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—testicular cancer	0.00125	0.00129	CcSEcCtD
Methyldopa—Oedema—Epirubicin—testicular cancer	0.00123	0.00127	CcSEcCtD
Methyldopa—Infection—Epirubicin—testicular cancer	0.00122	0.00126	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—testicular cancer	0.0012	0.00125	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—testicular cancer	0.0012	0.00125	CcSEcCtD
Methyldopa—ADRA2A—testis—testicular cancer	0.0012	0.034	CbGeAlD
Methyldopa—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.0012	0.00124	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—testicular cancer	0.00119	0.00124	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—testicular cancer	0.00119	0.00123	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—testicular cancer	0.00119	0.00123	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—testicular cancer	0.00118	0.00122	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00118	0.00122	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—testicular cancer	0.00114	0.00118	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00113	0.00117	CcSEcCtD
Methyldopa—Infection—Doxorubicin—testicular cancer	0.00113	0.00117	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00112	0.00116	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—testicular cancer	0.00111	0.00116	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—testicular cancer	0.00111	0.00115	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—testicular cancer	0.0011	0.00114	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—testicular cancer	0.0011	0.00114	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00106	0.0011	CcSEcCtD
Methyldopa—Constipation—Epirubicin—testicular cancer	0.00105	0.00109	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—testicular cancer	0.00104	0.00108	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00104	0.00107	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—testicular cancer	0.00102	0.00106	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000981	0.00102	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—testicular cancer	0.000972	0.00101	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—testicular cancer	0.000971	0.00101	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—testicular cancer	0.000967	0.001	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—testicular cancer	0.000942	0.000976	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—testicular cancer	0.000905	0.000938	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—testicular cancer	0.000898	0.000931	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—testicular cancer	0.000898	0.000931	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—testicular cancer	0.000881	0.000913	CcSEcCtD
Methyldopa—ADRA2A—lymph node—testicular cancer	0.000868	0.0246	CbGeAlD
Methyldopa—Dizziness—Methotrexate—testicular cancer	0.000868	0.0009	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—testicular cancer	0.00084	0.000871	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—testicular cancer	0.000837	0.000868	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—testicular cancer	0.000834	0.000865	CcSEcCtD
Methyldopa—Rash—Methotrexate—testicular cancer	0.000827	0.000858	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—testicular cancer	0.000827	0.000857	CcSEcCtD
Methyldopa—Headache—Methotrexate—testicular cancer	0.000822	0.000852	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—testicular cancer	0.000815	0.000845	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—testicular cancer	0.000812	0.000842	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—testicular cancer	0.000781	0.000809	CcSEcCtD
Methyldopa—Nausea—Methotrexate—testicular cancer	0.00078	0.000808	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—testicular cancer	0.000778	0.000806	CcSEcCtD
Methyldopa—Rash—Epirubicin—testicular cancer	0.000774	0.000803	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—testicular cancer	0.000774	0.000802	CcSEcCtD
Methyldopa—Headache—Epirubicin—testicular cancer	0.000769	0.000798	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—testicular cancer	0.000751	0.000779	CcSEcCtD
Methyldopa—Nausea—Epirubicin—testicular cancer	0.00073	0.000756	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—testicular cancer	0.000723	0.000749	CcSEcCtD
Methyldopa—Rash—Doxorubicin—testicular cancer	0.000717	0.000743	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—testicular cancer	0.000716	0.000742	CcSEcCtD
Methyldopa—Headache—Doxorubicin—testicular cancer	0.000712	0.000738	CcSEcCtD
Methyldopa—Nausea—Doxorubicin—testicular cancer	0.000675	0.0007	CcSEcCtD
